Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Summary

This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Advanced Biliary Tract Carcinoma
• Advanced Head and Neck Squamous Cell Carcinoma
• Advanced Hepatocellular Carcinoma
• Advanced Lung Non-Small Cell Carcinoma
• Advanced Malignant Solid Neoplasm
• Advanced Melanoma
• Advanced Renal Cell Carcinoma
• Metastatic Biliary Tract Carcinoma
• Metastatic Head and Neck Squamous Cell Carcinoma
• Metastatic Hepatocellular Carcinoma
• Metastatic Lung Non-Small Cell Carcinoma
• Metastatic Malignant Solid Neoplasm
• Metastatic Melanoma
• Metastatic Renal Cell Carcinoma
• Recurrent Head and Neck Squamous Cell Carcinoma
• Stage III Hepatocellular Carcinoma AJCC v8
• Stage III Lung Cancer AJCC v8
• Stage III Renal Cell Cancer AJCC v8
• Stage IV Hepatocellular Carcinoma AJCC v8
• Stage IV Lung Cancer AJCC v8
• Stage IV Renal Cell Cancer AJCC v8

Eligibility basics and study details

Study type

Interventional

Phase

Phase 4

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

OHSU Knight Cancer Institute

Last updated on ClinicalTrials.gov

October 13, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites